Supplementary Table 2

Compound Relevance to General Known Protein Target Class Name AML therapy group

epigenetic Azacitidine DNA methyltransferase in clinic HMAs modifiers epigenetic Valproic acid HDAC histon deacetylase phase II HDAC inhibitor modifiers Tretinoin retinoic acid receptor in clinic Differentiation Other Navitoclax bcl2, bcl-xl, bcl-w preclinical bcl2 inhibitors apoptotic ABT 737 bcl2, bcl-xl, bcl-w preclinical bcl2 inhibitors apoptotic Selumetinib MEK1/2 phase II MEK inhibitor MEK inhibitor mTOR/PI3K Signaling Dactolisib mTOR/PI3K preclinical inhibitor inhibitors CDK4/6 Cell cycle Palbociclib CDK6 preclinical inhibitor inhibitor Kinase Dasatinib bcr-abl, src, c-kit phase III Kinase inhibitor inhibitors Lenalidomide unclear phase II Other Other Aurora B Cell cycle Barasertib Aurora B phase I inhibitor inhibitors Signaling Rigosertib ras mimetics phase I/II PLK inhibitor inhibitors Signaling Vismodegib SMO preclinical PLK inhibitor inhibitors flt3, c-KIT, Kinase Quizartinib PDGFR phase III FLT3 inhibitor inhibitors

Kinase SGI-1776 pim kinase preclinical FLT3 inhibitor inhibitors Signaling BKM120 PI3K preclinical PI3K inhibitor inhibitors ras mutated Trametinib mek1/2 MEK inhibitor MEK inhibitor preclinical Signaling INK 128 mTORC1/2 preclinical mTOR inhibitor inhibitors Kinase Crenolanib Flt3, PDGFRα/ß flt3 mutated Flt3 inhibitor inhibitors Venetoclax BCL2, bcl-xl, bcl w in clinic bcl2 inhibitors apoptotic combination HDAC epigenetic Panobinostat HDAC with HMA inhibitors modifiers phase I/II Bromodomain and epigenetic OTX015 extraterminal (BET) phase I BET inhibitor modifiers proteins PIM kinase Kinase AZD1208 pan pim kinase preclinical inhibitor inhibitors epigenetic JQ1 Bet protein bromodomain preclinical BET inhibitor modifiers

6

Selinexor XPO1 phase I XPO1 inhibitor

epigenetic PTC-209 BMI1 preclinical BMI1 inhibitor modifiers Proteosome Proteosome Bortezomib proteosome phase II inhibitor inhibitor Proteosome Proteosome Carfilzomib proteosome preclinical inhibitor inhibitor Cytarabine cytosine deoxyribose in clinic antimetabolites chemotherapy purine nucleoside Purine Clofarabine phase II chemotherapy analogue analogue deoxynucleoside epigenetic Decitabine in clinic HMAs analogue of cytidine HMA modifiers Purine Fludarabine purine analog in clinical chemotherapy analogue JAK1/2 Kinase Ruxolitinib JAK1/2 phase II inhibitor inhibitors Topoisomerase Etoposide Topoisomerase II in clinic chemotherapy II inhibitor Signaling Temsirolimus mTOR phase I mTOR inhibitor inhibitors Signaling Everolimus mTOR phase Ib mTOR inhibitor inhibitors Purine Cladribine purine analogue phase II chemotherapy analogue PLK1 Cell cycle Volasertib Polo-like kinase 1 Phase III antagonist inhibitor lysine specific epigenetic LSD1 preclinical LSD1 inhibitor demethylase 1(LSD-1) modifiers PU-H71 HSP90 preclinical

histone 3 lysine 79 (H3K79) MLL, DNMT3A DOT1L epigenetic Pinometostat methyltransferase mutant inhibitor modifiers DOT1L Kinase G-749 flt3 FLT3 mutation FLT3 inhibitor inhibitors Kinase Pexidartinib CSF1R, kit,flt3 FLT3 mutation FLT3 inhibitor inhibitors MDM2 Cell cycle RG7112 MDM2 antagonist phase II antagonist inhibitor Flt3, c-KIT, PKC, Kinase Midostaurin PDGFR, in clinic FLT3 inhibitor inhibitors VEGFR mutated isocitrate differentiation epigenetic Ivosidenib dehydrogenase type 1 in IDH1 IDH1 inhibitor modifiers (IDH1) mutated

7